In the main text, we have assigned the lower band the 15-mer peptide fMSKAKFARTKPHANA and the upper band the full-length product fMSKAKFARTKPHANAxHHHHHH. This is corroborated by the following evidence: If we translate template 'O' in presence of RF2 to produce a defined stop after 15 amino acids, we find only the lower band ( Figure S4A and B, lane 5), while we find exclusively the upper band if we translate template 'G 1 ' in presence of glycine and GlyRS (lane 4). Translating template 'G 1 ' in absence of glycine/GlyRS without or with added deacyl-tRNA Gly u yields the lower band and a weak upper band (lanes 1 and 2, respectively). The weak upper band observed under these conditions most likely arises from unspecific readthrough of the hungry codon at position 16 during the prolonged incubation time (3 hours at 37°C); we observed the same effect with a hungry tyrosine-specific codon at position 16 and with template 'O' in absence of RF2 (not shown). If we additionally omit L-histidine, we find no band at all (lane 3), suggesting that the histidine residue at position 12 is essential for co-purification of the lower band. The LC-MS data shown in Figure 6 demonstrated the formation of full-length products in response to the addition of L-Trp-tRNA Gly or D- Trp-tRNA Gly to the translation reaction. In the negative control reaction of that experiment, which contained only deacyl-tRNA Gly , we were able to detect an abundant mass that precisely matches the calculated mass of the proposed 15-mer peptide (m calc = 1684.88 Da) and heavier isotopes of it ( Figure S4C ). pASG-IBA103 (anhydrotetracycline-inducible, C-terminal Twin-Strep Tag) for aspartyl-tRNA synthetase (AspRS), cysteinyl-tRNA synthetase (CysRS), glutaminyl-tRNA synthetase (GlnRS), glutamyl-tRNA synthetase (GluRS), histidinyl-tRNA synthetase (HisRS), leucyl-tRNA synthetase (LeuRS), lysyl-tRNA synthetase (LysRS), prolyl-tRNA synthetase (ProRS), seryl-tRNA synthetase (SerRS), tryptophanyl-tRNA synthetase (TrpRS), tyrosyltRNA synthetase (TyrRS), valyl-tRNA synthetase (ValRS), elongation factor 4 (EF4), elongation factor Tu (EF-Tu) and mutants thereof, release factor 3 (RF3).
* GlyRS consists of two only loosely coupled chains, tagging only one entails loss of the other during affinity chromatography. Thus, both encoding cistrons were first cloned into pASG-IBA103 to fuse the -subunit to a C-terminal TwinStrep-tag and the fused gene was subcloned into pASG-IBA105 to fuse the -subunit to an Nterminal TwinStrep-tag. PheRS also consists of two subunits that are tightly coupled, so one tag is sufficient.
The gene lepA encoding EF4 was synthesized and subcloned into a StarGate-compatible vector by GeneArt. The gene encoding RF2 harbors an inframe stop codon, expression of the protein requires a frameshift. This necessity was eliminated by site directed mutagenesis. All mutageneses were performed using the QuikChange Lightning site directed mutagenesis kit (Agilent). For verification, all plasmids were sequenced (LGC Genomics).
Expression plasmids were transformed into E.coli NEB Express (New England Biolabs). Cells were grown for 20 h at 30°C in 50-200 ml of EnPresso medium (BioSilta), expression was then induced for 24 h by the addition of anhydrotetracycline to 200 ng/ml, the temperature was increased to 37°C. For RF3 expression, cells were grown to 0.7 OD 600 /ml at 37°C in 2YT-medium and induced for 4 h.
Cells were harvested by centrifugation (20 min, 4°C, 6,000 x g), resuspended in Buffer W (100 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA) and lysed by two or three passages at 500 bar through a French®Press (Thermo Electron). Cell debris was pelleted by centrifugation (30 min, 4°C, 15,500 x g). The supernatant was filtered through 0.8/0.2 µm syringe filters (PALL) and subjected to affinity chromatography (AC) over StrepTrap HP 5 ml columns using an ÄKTA Express instrument (GE Healthcare). Buffer W was used for binding and washing, elution was done in the same buffer supplemented with 2.5 mM desthiobiotin (IBA GmbH). For all except IF1 and IF3, fractions were pooled and diluted in 20 mM Tris-HCl pH 8.0, 10 mM KCl and subjected to anion exchange chromatography over HiTrap Q HP 5 ml columns (GE healthcare) in the same buffer with a gradient from 10 mM to 500 mM KCl during 20 column volumes (CV). Purification of both EF-Tu and EF-Ts required a 40 CV gradient, as these proteins co-elute from AC and have a near-identical pI.
IF2 co-elutes from AC with 30S ribosomal subunits. 16S rRNA was eliminated by anion exchange. Ribosomal proteins were subsequently eliminated by a second AC.
mM HEPES-KOH pH 7.6 @ 0°C, 100 mM KCl, 10 mM MgCl 2 , 7 mM -mercaptoethanol, 30% glycerol) by buffer addition and re-concentration, and were finally flash-frozen in liquid nitrogen and stored in aliquots at -80°C.
To determine specific protein concentrations, dilutions of the proteins and serial dilutions of bovine serumalbumine (Pierce) were subjected to 10% Bis-Tris SDS-PAGE (novex). Gels were stained with SyproRed (Molecular Probes) according to the manufacturer's instructions and scanned using a MolecularImager FX (Bio-Rad). Band intensities were quantified using ImageLab software (Bio-Rad). This method is independent of the amino acid composition of the proteins, inert to any components of the protein storage buffer and does not co-quantify contaminating proteins of different size if any are present.
Assembly of the translation system Solution 1 (10x) contains 500 mM HEPES, 1 M potassium acetate, [20 mM ATP, 20 mM GTP, 10 mM CTP, 10 mM UTP (Jena Bioscience)], 200 mM creatine phosphate (Sigma), 1 mM 10-formyl- 5, 6, 7, 8 tetrahydrofolate (fTHF) , 15 mg/ml bulk tRNA from E. coli MRE600 (Roche), [20 mM spermidine, 10 mM dithiothreitol (Applichem)]. fTHF was prepared from folinic acid calcium salt (Applichem) as described (1). Prior to addition, bulk tRNA was deacylated following ref (2) by incubation at 37°C for one hour in 0.05 mM sodium borate and desalted in H 2 O over a NAP5 column (GE Healthcare). Before the addition of spermidine and DTT, the pH was adjusted to 7.60 on ice using KOH. Meeting the final volume required concentration in a Speedvac in between.
Solution 2 (16.67x) contains 5 mM each of the amino acids required for the intended purpose. The pH was adjusted to 7.60 on ice using acetic acid or KOH (depending on the composition).
Solution 3 (20x) contains 20.4 µM IF1, 8 µM IF2, 9 µM IF3, 12.6 µM EF-G, 31.6 µM EF-Ts, 4.8 µM RF-1, 3.2 µM RF-3, 9.4 µM RRF, 80 µg/mL creatine kinase (Roche), 2.4 µM ADK, 1.3 µM NDK, 280 µM iPPase, 100 µg/ml T7 RNAP (Stratagene), and 24 µM reassociated 70S ribosomes. For assembly, proteins were mixed in an Amicon Ultra 0.5 ml centrifugal filter column (3 kDa MWCO, Millipore) and concentrated. Stock buffer (see above) was added to 450 µl and concentrated again. Ribosomes were added last to make sure that they will not dissociate due to low magnesium conditions. Several cycles of concentration and addition of stock buffer were performed, until a buffer exchange of at least 99% was achieved. The desired final volume was adjusted with stock buffer. Single-use aliquots were flash-frozen in liquid nitrogen and stored at -80°C. 
Oligonucleotide synthesis
All primers, Flexizymes and unmodified tRNAs were synthesized by solid phase oligonucleotide synthesis using standard phosphoamidite chemistry on an ABI 392 (Applied Biosystems) or ÄKTA10 oligonucleotide synthesizers (GE-Healthcare). For RNA synthesis 2'-TBDMS protected phosphoamidites were used (3) (4) (5) . Phosphoamidites and CPGs were purchased from Proligo and Thermo Fisher and used according to the manufacturer's instruction. Ultrafast-, rT-, pseudo-rU-, 4-thio-rU-, dihydro-rU-as well as bis-cyanoethylamidites were from ChemGenes. Identity and purity of all oligonucleotides was confirmed by RP-and IEX-HPLC and LC-MS (ESI-). 
Primer sequences

Assembly of native tRNA Gly
Due to the special and mutually incompatible deprotection requirements of 4-thiouridine and dihydrouridine, native tRNA Gly was synthesized in three fragments, which were then ligated in two separate steps. Separate ligation steps were required to prevent an otherwise observed direct ligation of fragment 1 to fragment 3. For coupling rG(Pac), rA(Pac) were used instead of rG(ibu) and rA(bz) amidites. The quantitative coupling of the 4-thiouridine building block was achieved by double coupling of the amidite. Oxidization of phosphit triesters was achieved using 0.02M iodine in pyridine/H 2 O (9/1, v/v). Tac 2 O served as capping reagent (Proligo fast deprotection capping reagent). After completed oligonucleotide assembly, the CPG was transferred into a glass bottle and dried under reduced pressure. For the removal of cyanoethyl protective groups 10 ml 1M DBU in ACN was added to the dry support at RT. After 2h the supernatant was discarded and the residue CPG was washed 5x with 20 ml ACN. To facilitate cleavage of the oligonucleotide from the CPG 15 ml of 50mM NaSH solution in tBuNH 2 /MeOH/H 2 O (1/1/2, v/v/v) were added and agitated for 3h at 55°C. After cooling, the supernatant was purified by size exclusion chromatography using NAP25 columns (GE-Healthcare) according to the manufacturer's instructions. The product containing fractions were pooled and freeze dried. Purification was done with IEX-chromatography Source15Q (GE-Healthcare) using 25 mM Tris buffer pH 7.5, 10 %ACN, 2M NaCl at 55°C followed by size exclusion chromatography (NAP10, GE-Healthcare). Yield: 60 OD, 2.40 mg, 798nmol.
Synthesis of native tRNA
Gly fragment 2: Synthesis was commenced on 0.32g 1000A rA(Pac) CPG (41µmol/g).
For coupling rG(Pac), rA(Pac) were used instead of rG(ibu) and rA(bz) amidites. The quantitative introduction of the dihydrouridine building block was achieved by double coupling of the amidite. Oxidization of phosphit triesters was achieved using 0.05M iodine in pyridine/H 2 O (9/1, v/v). Tac 2 O (Proligo fast deprotection capping reagent) was used as a capping reagent. After completed oligonucleotide assembly, the CPG was washed for 10 min with 10% Et 2 NH in ACN followed by a thorough 10 min wash with ACN for removal of the cyanoethyl protective goups. Finally the CPG was transferred into a glass bottle and dried under reduced pressure. To facilitate cleavage of the oligonucleotide from the CPG 20 ml of 50mM NaSH solution in 28% NH 3 (aq.) were added and agitated for 4h at 25°C. The supernatant was collected, concentrated and purified by size exclusion chromatography using NAP25 columns (GE-Healthcare) according to the manufacturer's instructions. The product containing fractions were pooled and freeze dried. Purification was done with IEX-chromatography Source15Q (GE-Healthcare) using 25 mM Tris buffer pH 7.5, 10 %ACN, 2M NaCl at 55°C followed by size exclusion chromatography (NAP10, GE-Healthcare). Yield: 35 OD, 1.40 mg, 392 nmol.
Synthesis of native tRNA Gly fragment 3: Synthesis was carried out using standard conditions as described above.
Ligation step 1:
Triplicates of 200 µl of 10x T4 RNA Ligase 2 buffer (NEB), 15.51 nmol each of tRNA fragment 2 (nucleotides 10-20), fragment 3 (nucleotides 21-76), a complementary DNA strand spanning nucleotides 1-40 (sequence: AGCTTGGGAAGCTCTCGTTCTACCATTGAACTACGCCCGC) and H 2 O to 1973 µl were mixed and spread into 30 equal aliquots. The oligonucleotides were annealed by denaturing for 3 minutes at 95°C and cooling to 4°C at a rate of 0.2°C per second in a PCR cycler. To each aliquot, 30 µg T4 RNA ligase 2 per 1 nmol of fragment 3 were added (total reaction volume 2 ml). The reactions were incubated for 2 h at 37°C and precipitated by the addition of 0.1 volume of 3 M NaOAc pH 5.5 and 2.5 volumes of ethanol and subsequent centrifugation for 15 minutes at 21,500 x g. All pellets were dissolved in a total of 200 µl of 8 M urea and applied to an 8 % TBE-Urea maxi gel. Bands were visualized by UV shadowing. The band of the ligation product was cut out, recovered by electroelution and desalted over a NAP10 column (GE healthcare). This procedure was executed twice, yielding ~9.41 nmol of ligation product (~10%).
Ligation step 2: 150 µl of 10x T4 RNA Ligase buffer (NEB), 9.41 nmol of ligated fragment (2+3), 18.82 nmol of fragment 1, H 2 O to 1.5 ml were mixed and spread into eight equal aliquots of 185 µl. Annealing was done as decribed above. To each aliquot, 8 µg of T4 RNA ligase 2 per nmol of fragment 2+3 were added. The reactions were incubated for 2h at 37°C. Precipitation and purification of the ligation product was performed as described above. The final overall yield was ~520 pmol (~1.1%).
Judged by TBE-Urea-PAGE, the yield of both ligation reactions was about 90% (step 1) and 50% (step 2), but the recovery from the purification procedure was poor. Due to the low overall yield, native tRNA Gly could not be used for routine experiments.
Synthesis of (D)-aa-Flexizyme substrates
Synthesis of Flexizyme substrates was commenced from commercially available (D)-amino acid species. If necessary, -amino-as well as side chain protective groups were introduced by known protocols (7) (8) (9) . Amino acid building blocks were then reacted to form ABT, DBE or CME esters. As amino acids can undergo racemization upon activation, the reaction conditions have to be selected carefully (10). In most cases, PyBOP (11, 12) The enantiopurity of the final products was determined by C.A.T. GmbH. The protective group pattern, the promoter group introduced to each amino acid and esterification method used as well as the enantiopurity of the final product is given in the table below. 
Chemical synthesis procedures
A) PyBOP, H-ABT(Boc); B) EDC/HOBt, H-ABT(Boc); C) NEt3, DBE-Cl;
General Procedure 1 (Thioesterification): At room temperature the Boc-and eventually side chain protected amino acid was dissolved in DMF (0.1 M), 0.95 eq. PyBOP and 2 eq. DÌPEA were added. After 2 min, 1 eq. H-ABT(Boc) was added and the resulting mixture was stirred for 30 min at room temperature. The reaction was quenched by addition of aq. sat. NaHCO 3 solution and extracted with EtOAc (3x). The organic phase was washed with water (2x), brine (1x), dried over Na 2 SO 4 and concentrated to dryness. Purification by flash column chromatography yielded the desired product.
General Procedure 2 (Boc-cleavage):
At room temperature the Boc-and eventually side chain protected amino acid ABT thioester was dissolved in DCM (2 ml/mmol) and 4 M HCl in dioxane (abs.) was added. After stirring for 2h, the reaction was concentrated to dryness and co-evaporated with toluene two times. 4, 28.6, 28.7 (4tBu) , 32.0 (S-CH 2 ), 61.0 (CH), 78.1, 78. 5, 79.1, 83.3 (4C q ), 127.8, 128.9 (2x2ArCH), 133.7, 141.5 (2ArC q ), 152.5, 155.7, 155.9, 156.2 (2BocC q 
Synthesis of Boc-(D)-Ala-ABT(Boc):
Synthesis of Boc-(D)-Asn-ABT(Boc):
At room temperature the 339 mg (1.46 mmol) Boc-(D)-Asn-OH and 198 mg (1.29 mmol) HOBt were dissolved in 17 ml DMF. Subsequently 266 mg (1.39 mmol) EDC followed by 500 mg (1.61 mmol) H-ABT(Boc) were added. After 1 hour at room temperature, the reaction mixture was distributed between EtOA and aq. sat. NaHCO 3 solution and extracted with EtOAc (3x). The combined organic phase was washed with 0.1 M HCl (1x) and brine (1x), dried over Na 2 SO 4 
Synthesis of H-(D)-
Synthesis of Boc-(D)-Cys(Trt)-ABT(Boc):
Following general procedure 1 with minor modifications, 1.39 g (3.00 mmol) Boc-(D)-Cys(Trt)-OH was reacted with 1.48 g (2.85 mmol) PyBOP, 1.02 ml (6.00 mmol) DIPEA and 0.621 mg (2.00 mmol) H-ABT(Boc) in 20 ml DMF. Yield: 1.22 g (1.61 mmol, 80.6 %), colorless solid. Flash column chromatography: Hexane/EtOAc (3/2, v/v), R f : 0.66 (Hexane/EtOAc, 1/3, v/v). 
Synthesis of H-(D)-Glu-ABT × 2 HCl:
Following general procedure 2, 630 mg (1.06 mmol) Boc-(D)-Glu(OtBu)-ABT(Boc) dissolved in 1.00 mL DCM was treated with 2.00 ml 4M HCl in Dioxane (abs.) to yield 530 mg (1.28 mmol) H-(D)-Glu-ABT as a brown solid. 
Synthesis of H-(D)-Ile-ABT × 2 HCl:
Following general procedure 2, 1.70 g (3.25 mmol) Boc-(D)-Ile-ABT(Boc) dissolved in 6.5 ml DCM was treated with 12.9 ml 4M HCl in Dioxane (abs.) to yield 1.36 g (3.43 mmol) H-(D)-Ile-ABT as off-white foam. 
Synthesis of Boc-(D)-Leu-ABT(Boc):
Following general procedure 1, 870 mg (3.76 mmol) Boc-(D)-Leu-OH was reacted with 1.85 g (3.57 mmol) PyBOP, 1.28 ml (7.52 
Synthesis of H-(D)-Leu-ABT × 2 HCl:
Following general procedure 2, 1.43 g (2.73 mmol) Boc-(D)-Leu-ABT(Boc) dissolved in 5.5 ml DCM was treated with 10.9 ml 4M HCl in Dioxane (abs.) to yield 1.00 g (2.52 mmol) H-(D)-Leu-ABT as a colorless solid. 6.77 (1H, t, BocNH), 6.90 (1H, t, BocNH), 7.34 (2H, d, 2ArCH), 7.60 (1H, d, BocNH), 7.74 (2H, d, 2ArCH), 8.40 (1H, t, AmidNH) . 13 C-NMR (DMSO-d6) δ (ppm): 23.2 (CH 2 ), 28. 6, 28.7, 28.7 (3tBu), 29.4, 30.9 (2CH 2 ) , 31.9 (S-CH 2 ), 61.2 (CH), 77. 8, 78.1, 79.1 (3C q ), 127.8, 128.9 (2x2ArCH), 133.7, 141.6 (2ArC q 7.42 (2H, d, 2ArCH), 7.92 (2H, d, 2ArCH) 
Synthesis of Boc-(D)-Met-DBE:
In a 25ml flask, 1.10 g (4.40 mmol) Boc-(D)-Met-OH were dissolved in 5 ml DMF. To this solution 516 µl (7.48 mmol) DIPEA and 810 mg (3.74 mmol) 3,5-dinitrophenyl chloride were added. The reaction was stirred at room temperature. After 16 h, Et 2 O (100 mL) and 0.5M HCl (100 ml) were added, the organic phase was separated, washed with 0.1M HCl (2x, 100 ml), dried over Mg 2 SO 4 and concentrated under reduced pressure. The crude product was further purified by flash column chromatography (Hexane/EtOAc, 5/1, v/v) 8.67 (2H, d, 2ArCH), 8.80 (1H, t, 1ArCH 8.77 (2H, m, 2ArCH), 8.81 (1H, m, 1ArCH), 8.93 (3H, br, NH 3 + ). 6.86 (1H, t, BocNH), 7.20 (5H, m, 5ArCH), 7.32 (2H, d, 2ArCH), 7.65 (1H, d, BocNH), 7.73 (2H, d, 2ArCH), 8.39 (1H, t, AmidNH 9, 128.7, 129.1, 129.6 (4x2ArCH), 133.8, 137.9, 141.6 (3ArC q ), 155.8, 156.3 (2BocC q ), 166.6 (AmidC q ), 201.8 (Thioester-C q ). 4.48 (1H, m, CH), 7.42 (2H, d, 2ArCH), 7.17 (2H, m, 2ArCH), 7.25 (3H, m, 3ArCH), 7.31 (2H, m, 2ArCH), 7.91 (2H, d, 2ArCH), 8.32 (3H, br, NH 3 + ), 8.95 (1H, t, AmidNH).
Synthesis of H-(D)-
13
C-NMR (DMSO-d6) δ (ppm): 32.5 (S-CH 2 ), 37.4 (CH 2 ), 37.6, 39.0 (2N-CH 2 -), 59.7 (CH), 127.8 (ArCH), 128.1, 129.0, 129.1, 130.0 (4x2ArCH), 133.3, 134.7, 140.8 (3ArC q ), 166.6 (AmidC q ), 196.1 (Thioester-C q ).
Synthesis of Boc-(D)-Pro-ABT(Boc):
Following general procedure 1 with minor modifications, 646 mg (3.00 mmol) Boc-(D)-Pro-OH was reacted with 1.48 g (2.85 mmol) PyBOP, 1.02 ml (6. C-NMR (2 Rotamers) (DMSO-d6) δ (ppm): 23.5, 24.2 (CH 2 ), 28. 2, 28.5, 28.7 (2tBu), 30.6, 31.5 (CH 2 ), 31.8, , 46.9, 47.1 (CH 2 ), 66.1 (CH), 78.1, 79.8, 79.9 (2C q ), 127.8 (ArCH), 128.8, 128.9 (ArCH), 133.7, 133.7, 141.5, 141.8 (2ArC q ), 153.3, 154.2, 156.2 (2BocC q 
Synthesis of Boc-(D)-Ser(tBu)-ABT(Boc):
Following general procedure 1, 523 mg (2.00 mmol) Boc-(D)-Ser(tBu)-OH was reacted with 988 mg (1.90 mmol) PyBOP, 680 µl (4.00 mmol) DIPEA and 621 mg (2.00 mmol) H-ABT(Boc) in 20 ml DMF. Yield: 606 mg (1.09 mmol, 57.6 %), brown solid. Flash column chromatography: Hexane/EtOAc (6/4, v/v) .27 (1H, t, BocNH), 6.70 (1H, d, 7.10 (2H, d, 2ArCH), 7.31 (2H, d, 2ArCH), 7.42 (2H, d, 2ArCH), 7.85 (3H, m, 2ArCH , Amid-NH). 13 C-NMR (Acetone-d6) δ (ppm): 27.6, 27.7 (2tBu), 32.1 (S-CH 2 ), 36.5 (CH 2 ), 62.1 due to TCs dissociated during gel electrophoresis) and one right above the TC band that defines the background for that lane.
Activity test of EF-Tu mutants by GFP translation
A mastermix was prepared comprising per reaction H 2 O to a final reaction volume of 20 µl, 2 µl of SUPERaseIn (Ambion), 2 µl of 120 mM Mg(OAc) 2 , 2 µl Solution 1, 1.2 µl Solution 2 (all canonical amino acids), 1 µl Solution 3, 1 µl Solution 4 (all aaRS), and 1 µl of 200 ng/µl pRSET/EmGFP (Intitrogen). The mastermix was spread to white twin.tec 96-well real-time PCR plates (Eppendorf). 2 µl of 2,000 ng/µl wild-type-EF-Tu or mutant EF-Tu in EF-Tu storage buffer (see above) were added and mixed by pipetting. The plates were sealed and incubated at 37°C in a PolarStar Optima microplate reader (BMG lab technologies). Fluorescence was measured by excitation at 485 nm and detection at 520 nm wavelength every ten min. until it reached a plateau. S-Met (SCM-01; Hartmann Analytics) was spread to the prepared reaction vessels. The final magnesium concentration is 13 mM (1 mM from solutions 3 and 4). The reactions were incubated for 3 h at 37°C. For double and triple incorporation experiments, the final EF-Tu concentration was doubled and EF4 was added to 0.36 µM (0.3 ribosome equivalents). For purification of the translated peptides, 20 µl of Ni-NTA-Agarose (Qiagen) were spun dry in MoBiSpin F columns (MoBiTec) and equilibrated with 200 µl of 50 mM Tris-HCl pH 7.5, 500 mM NaCl, 20 mM imidazole. 90 µl of the same buffer and one reaction of 10 µl were added and shaken at 750 rpm at 4°C for 1 h. The columns were spun dry, washed with 200 µl of water, and eluted twice with 100 µl each of 10% formic acid. The eluates were dried in a SpeedVac and subjected to 16% TRICINE-SDS PAGE (2 h at 125 V, gels and buffers from novex). Phosphorimager-Screens (K-Screens, Kodak) were exposed for 3-4 days and scanned using a MolecularImager FX (Bio-Rad) at 50 µm resolution (508 dpi).
For relative quantification of bands using ImageLab software (Bio-Rad), free-hand volumes were defined precisely around the bands and background was subtracted globally. Care was taken not to underestimate bands of L-aa or control reactions as well as not to overestimate bands of D-aa reactions.
Diastereomeric peptide separation method and mass spectrometric detection. The RP-HPLC method for separation of the D-and L-peptide isomers was established on synthetic peptides (formyl-MSKAKFARTKPHANA[(D-W or L-W)]HHHHHH), monoisotopic mass 2693.3 Da; Biosyntan). Furthermore, these peptides were used for translation sample spiking as well as a standard mixture for LC-MS performance control before and after sample analysis. As an internal standard for the entire LC-MS performance, the synthetic tripeptide VYV (Sigma-Aldrich, MW 379.2Da, detectable in a single charge state of M+H + with 380.2 m/z) was added to each sample. Separation has been achieved using an Agilent 1290 chromatographic system (Agilent Technologies) and accurate mass analysis using an online coupled ESI -QTOF 6520 (Agilent Technologies) mass spectrometer. Samples were injected into an Acquity UPLC BEH300 C18 column (2.1 x 100mm, 1.7µm particle size, 300Å pore size; Waters) and desalted for 0.7 minutes before switching the flow online to the MS. Elution was performed with a gradient of solvent A and B in 30 minute runs: after 3 min. of desalting with 100% solvent A, separation was performed with 0-15% solvent B in 17 min. followed by a column wash with 15-80% solvent B in 1 min. 80% solvent B was kept for 2 min. to elute the
